Stories from people navigating HRR mutations — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Oncology
The FDA has expanded talazoparib plus enzalutamide to selected adults with HRR-mutated metastatic castration-sensitive prostate cancer. Treatment requires mutation confirmation with an FDA-authorized test.
Rayan Salih · November 10, 2026 · 7 min
Oncology
The FDA approved talazoparib plus enzalutamide for adults with HRR-mutated metastatic prostate cancer that remains naïve or sensitive to androgen-pathway modulation. An FDA-authorized test must confirm eligibility.
Dr. Abu Bakar · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.